ProShare Advisors’s Relmada Therapeutics RLMD Stock Holding History

ProShare Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,537	Closed	-$205K	–	1879
2022 Q3	$205K	Buy	+5,537	New	+$153K	﹤0.01%	1398
2022 Q2	–	Sell	-7,526	Closed	-$203K	–	2063
2022 Q1	$203K	Buy	+7,526	New	+$156K	﹤0.01%	1879
2021 Q3	–	Sell	-6,910	Closed	-$221K	–	2215
2021 Q2	$221K	Buy	6,910 +745	+12%	+$25.9K	﹤0.01%	2094
2021 Q1	$217K	Buy	+6,165	New	+$216K	﹤0.01%	1992

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ProShare Advisors's RLMD Position: Q4 2022 in Review

ProShare Advisors sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 5,537 shares — an estimated $205K sold.

ProShare Advisors first reported a position in RLMD in Q1 2021 and held it in 4 quarters. The position peaked at $221K in Q2 2021. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

ProShare Advisors reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
ProShare Advisors sold 5,537 Relmada Therapeutics shares in Q4 2022, an estimated $205K.
ProShare Advisors first reported a position in Relmada Therapeutics in Q1 2021 and held it in 4 quarters.
ProShare Advisors's Relmada Therapeutics position peaked at $221K in Q2 2021.
110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on ProShare Advisors's 13F filing for Q4 2022, filed 2 Feb 2023.